Literature DB >> 20404119

Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.

Florence Tchouaffi-Nana1, T Eric Ballard, Christine H Cary, Timothy L Macdonald, Costi D Sifri, Paul S Hoffman.   

Abstract

Coagulase-negative species of Staphylococcus are often associated with opportunistic hospital-acquired infections that arise from the colonization of indwelling catheters. Here we show that the antiparasitic drug nitazoxanide (NTZ) and its active metabolite, tizoxanide (TIZ), are inhibitory to the growth of Staphylococcus epidermidis and other staphylococci, including methicillin-resistant Staphylococcus aureus strains, under aerobic and microaerobic conditions (MICs, 8 to 16 microg/ml). At sub-MIC levels, NTZ and TIZ also inhibited biofilm production under static conditions by strains of S. epidermidis and Staphylococcus haemolyticus with a 50% inhibitory concentration of approximately 2.5 microg/ml (8 microM). The 5-nitro group was required for biological activity, and a hydrophilic derivative of NTZ (AMIX) also inhibited biofilm formation. NTZ did not disperse the existing biofilm but did block further accumulation. Sub-MICs of NTZ had no effect on primary attachment to surfaces at either 4 or 37 degrees C. The inhibitory action of NTZ and TIZ, but not vancomycin, on biofilm production could be reversed by the addition of zinc salts (2.5 to 40 microM) but not other metals, suggesting that NTZ might target the zinc-dependent accumulation-associated protein (Aap) that mediates accumulation on surfaces. However, neither NTZ nor TIZ formed chelation complexes with zinc salts, based on spectrophotometric and nuclear magnetic resonance analyses, and addition of excess zinc to NTZ-grown bacteria (apo-Aap) did not restore the accumulation phenotype. Our studies suggest that sub-MIC levels of NTZ may affect the assembly or function of cell structures associated with the biofilm phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404119      PMCID: PMC2897279          DOI: 10.1128/AAC.00901-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model.

Authors:  M E Rupp; J S Ulphani; P D Fey; D Mack
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Bacterial biofilms: an emerging link to disease pathogenesis.

Authors:  Matthew R Parsek; Pradeep K Singh
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

3.  Evaluation of a novel method based on PCR Restriction Fragment Length Polymorphism Analysis of the tuf gene for the identification of Staphylococcus species.

Authors:  F Kontos; E Petinaki; I Spiliopoulou; M Maniati; A N Maniatis
Journal:  J Microbiol Methods       Date:  2003-11       Impact factor: 2.363

4.  In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.

Authors:  L Dubreuil; I Houcke; Y Mouton; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers.

Authors:  A Stockis; X Deroubaix; R Lins; B Jeanbaptiste; P Calderon; J F Rossignol
Journal:  Int J Clin Pharmacol Ther       Date:  1996-08       Impact factor: 1.366

6.  A 140-kilodalton extracellular protein is essential for the accumulation of Staphylococcus epidermidis strains on surfaces.

Authors:  M Hussain; M Herrmann; C von Eiff; F Perdreau-Remington; G Peters
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

7.  Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial.

Authors:  D G Maki; S M Stolz; S Wheeler; L A Mermel
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

8.  Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis.

Authors:  C Heilmann; O Schweitzer; C Gerke; N Vanittanakom; D Mack; F Götz
Journal:  Mol Microbiol       Date:  1996-06       Impact factor: 3.501

9.  Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin.

Authors:  D Mack; M Nedelmann; A Krokotsch; A Schwarzkopf; J Heesemann; R Laufs
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis.

Authors:  D Mack; W Fischer; A Krokotsch; K Leopold; R Hartmann; H Egge; R Laufs
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

View more
  12 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

2.  Efficacy of antiamebic drugs in a mouse model.

Authors:  Stephen Becker; Paul Hoffman; Eric R Houpt
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

3.  Rsp inhibits attachment and biofilm formation by repressing fnbA in Staphylococcus aureus MW2.

Authors:  Mei G Lei; David Cue; Christelle M Roux; Paul M Dunman; Chia Y Lee
Journal:  J Bacteriol       Date:  2011-07-29       Impact factor: 3.490

4.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Paul S Hoffman; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-05-18       Impact factor: 2.823

Review 5.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

6.  Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Authors:  Paul S Hoffman; Alexandra M Bruce; Igor Olekhnovich; Cirle A Warren; Stacey L Burgess; Raquel Hontecillas; Monica Viladomiu; Josep Bassaganya-Riera; Richard L Guerrant; Timothy L Macdonald
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

7.  Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Authors:  Cirle A Warren; Edward van Opstal; T Eric Ballard; Andrew Kennedy; Xia Wang; Mary Riggins; Igor Olekhnovich; Michelle Warthan; Glynis L Kolling; Richard L Guerrant; Timothy L Macdonald; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 8.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  Amixicile, a novel strategy for targeting oral anaerobic pathogens.

Authors:  Justin A Hutcherson; Kathryn M Sinclair; Benjamin R Belvin; Qin Gui; Paul S Hoffman; Janina P Lewis
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

10.  Sulfenate Esters of Simple Phenols Exhibit Enhanced Activity against Biofilms.

Authors:  Danica J Walsh; Tom Livinghouse; Greg M Durling; Yenny Chase-Bayless; Adrienne D Arnold; Philip S Stewart
Journal:  ACS Omega       Date:  2020-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.